News
We send the latest information from SMC Laboratories.
CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC
CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. Resmetriom has been included in this pharmacology study, and its efficacy in treating fibrosis is directly compared with that of leronlimab. For detail information, see the CytoDyn’s press release. CytoDyn Announces Preliminary Findings in Study with…
Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.
We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (STAM™ model). The adiponectin‐derived peptide ALY688 protects against the development of metabolic dysfunction‐associated steatohepatitis – Huang – 2024 – Clinical and Translational Science – Wiley Online Library In this paper,…
Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (November 15-19). For detailed information, see the below URL. aasld.org/sites/default/files/2024-10/1_the_liver_meeting_2024_abstracts.pdf Poster #1060 The beneficial effect of resmetirom on tumorigenesis associated with MASH in STAM mice Institution: Kurume University School of Medicine (Japan) Poster #1082 Impact…
Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and after conducting pre-clinical studies in mice at our company, submitted the results of their research to Nature Biotechnology. This article identifies TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic…
Preclinical HCC study with positive control, Lenvatinib
We recently obtained new evaluation data on the Lenvatinib in our STAM model and it shows significantly improving effects on the Number, Size and Growth Rate of the tumor nodules in the liver as well as on the overall survival. (Please see the data below) …
Enhance Research with Our Updated Model Lineup
We are introducing new disease models to our portfolio of preclinical mouse models. Our extensive lineup offers comprehensive support for your research. The new models in our lineup: Obesity type MASH/NASH-HCC; GAN diet model The GAN diet model is a frequently used model for studies on obesity type MASH. We included this model…
Results of Resmetirom fibrosis targeting study using STAM™ model
Recently, we have obtained the results of a study of resmetirom for the treatment of fibrosis using STAMTM-HCC/IO+ model, and would like to share them with you. Resmetirom treatment confirmed improvement of steatosis score, NAFLD Activity score and fibrosis resolution effects. Thus, the STAMTM-HCC/IO+ model has been shown to show similar improvements in…
MOA demonstration #4 【Gut-Liver Axis】｜Evaluation of the efficacy of a compound in the treatment of MASH via the Gut-Liver Axis using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting Gut-Liver axis. In MASH patients, changes in the microbiome and increased intestinal permeability (Leaky Gut) have been observed (Lixin et al., Hepatology, 2012; Jay et al., CMGH, 2015). In fact, analyses in mouse models have shown that dysfunction of the gut-liver axis, such…
Case study: Study published in Biomolecules on the effects of MSC-sEV in skin fibrosis of BLM-SSc model.
We introduce a case study of drug efficacy evaluation of Mesenchymal stem/stromal cell-derived small extracellular vesicles (MSC-sEVs) using our Systemic sclerosis (SSc) model, BLM-SSc model. Title: An Assessment of Administration Route on MSC-sEV Therapeutic Efficacy ( Zhang B et al., Biomolecules. 2024 ) Article Link ► [DOI: 10.3390/biom14060622] In this study, we administered intraperitoneally, subcutaneously,…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Roflumilast) in a drug efficacy evaluation study using porcine pancreatic elastase (PPE)-induced COPD model. The drug used as a positive control is roflumilast, a PDE-4 inhibitor. Mean linear intercept by histological analysis of the lungs, the…